[go: up one dir, main page]

UA107814C2 - Спірооксіндольні антагоністи мdм2 - Google Patents

Спірооксіндольні антагоністи мdм2

Info

Publication number
UA107814C2
UA107814C2 UAA201207063A UAA201207063A UA107814C2 UA 107814 C2 UA107814 C2 UA 107814C2 UA A201207063 A UAA201207063 A UA A201207063A UA A201207063 A UAA201207063 A UA A201207063A UA 107814 C2 UA107814 C2 UA 107814C2
Authority
UA
Ukraine
Prior art keywords
mdm2
spirooxindol
angonogs
compounds
proposed
Prior art date
Application number
UAA201207063A
Other languages
English (en)
Russian (ru)
Inventor
Шаомен Ван
Шанхай Юй
Вей Сунь
Санджеєв Кумар
Дусінь Сунь
Пен Цзоу
Юйцзюнь ЧЖАО
Донна Макічерн
Original Assignee
Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43974649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107814(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган filed Critical Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган
Publication of UA107814C2 publication Critical patent/UA107814C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Запропоновані сполуки, композиції і способи в галузі медичної хімії. Запропоновані сполуки і композиції стосуються спірооксіндолів, які діють як антагоністи взаємодії р53 і MDM2, і їх використання як терапевтичних засобів для лікування раку і інших захворювань.
UAA201207063A 2009-11-12 2010-11-10 Спірооксіндольні антагоністи мdм2 UA107814C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26068509P 2009-11-12 2009-11-12
US26366209P 2009-11-23 2009-11-23
PCT/US2010/056197 WO2011060049A2 (en) 2009-11-12 2010-11-10 Spiro-oxindole mdm2 antagonists

Publications (1)

Publication Number Publication Date
UA107814C2 true UA107814C2 (uk) 2015-02-25

Family

ID=43974649

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207063A UA107814C2 (uk) 2009-11-12 2010-11-10 Спірооксіндольні антагоністи мdм2

Country Status (29)

Country Link
US (3) US8518984B2 (uk)
EP (1) EP2499145B1 (uk)
JP (1) JP2013510860A (uk)
KR (1) KR20120099462A (uk)
CN (2) CN104876938A (uk)
AR (1) AR079026A1 (uk)
AU (1) AU2010319595B2 (uk)
BR (1) BR112012011317A2 (uk)
CA (1) CA2780547C (uk)
CL (1) CL2012001250A1 (uk)
CO (1) CO6501131A2 (uk)
CR (1) CR20120313A (uk)
DO (1) DOP2012000131A (uk)
EC (1) ECSP12011943A (uk)
GT (1) GT201200147A (uk)
IL (1) IL219706A (uk)
MA (1) MA33815B1 (uk)
MX (1) MX2012005507A (uk)
NI (1) NI201200083A (uk)
NZ (1) NZ600430A (uk)
PE (1) PE20121282A1 (uk)
PH (1) PH12012500870A1 (uk)
RU (1) RU2553269C2 (uk)
TN (1) TN2012000161A1 (uk)
TW (1) TWI508967B (uk)
UA (1) UA107814C2 (uk)
UY (1) UY33029A (uk)
WO (1) WO2011060049A2 (uk)
ZA (1) ZA201203323B (uk)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのｍｄｍ２阻害剤のバイオマーカー
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
CN103298818B (zh) 2010-11-12 2016-06-29 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
PT2684880T (pt) 2011-03-10 2018-04-27 Daiichi Sankyo Co Ltd Derivado de dispiropirrolidina
CN103717605B (zh) * 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
WO2013101436A1 (en) * 2011-12-07 2013-07-04 Duke University Methods of identifying and using mdm2 inhibitors
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
CN103739566B (zh) * 2014-01-24 2016-01-20 中国人民解放军第三军医大学 含有磺酰胺的手性五元并环骨架化合物及制备方法和用途
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US9701685B2 (en) * 2014-08-18 2017-07-11 Hudson Biopharma Inc. Spiropyrrolidines as MDM2 inhibitors
JP6412753B2 (ja) * 2014-09-19 2018-10-24 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
JP6408318B2 (ja) * 2014-09-19 2018-10-17 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
US9962380B2 (en) 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
HUE054985T2 (hu) * 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123786C2 (uk) 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US9822128B1 (en) 2017-06-01 2017-11-21 King Saud University Substituted spirooxindoles
CN107312115B (zh) * 2017-06-22 2020-06-12 北京理工大学 一种双吲哚稀土金属催化剂、制备方法及应用
CN109988070B (zh) * 2017-12-29 2022-07-26 南京富润凯德生物医药有限公司 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
KR20210072043A (ko) 2018-10-08 2021-06-16 더 리젠츠 오브 더 유니버시티 오브 미시간 소분자 mdm 2 단백질 분해제
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
CN116194088A (zh) 2020-08-27 2023-05-30 大冢制药株式会社 使用mdm2拮抗剂治疗癌症的生物标志物
IL302990A (en) 2020-11-23 2023-07-01 Enanta Pharm Inc Novel spiropyrrolidine derived antiviral agents
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2022226426A1 (en) * 2021-04-24 2022-10-27 Universal Sequencing Technology Corporation A nanotrain for single-molecule detection
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
IL315583A (en) * 2022-03-18 2024-11-01 Enanta Pharm Inc Processes for the preparation of substituted spirooxindole derivatives
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) * 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
JPS444986Y1 (uk) 1966-10-20 1969-02-24
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JPH044986A (ja) 1990-04-20 1992-01-09 Nippon Stainless Steel Co Ltd ニッケル・ステンレス鋼クラッド材の製造方法
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
RU2084449C1 (ru) 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
ATE467418T1 (de) * 1997-01-20 2010-05-15 Immodal Pharmaka Gmbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
WO1999012904A1 (en) 1997-09-08 1999-03-18 Arqule, Inc. Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use
ATE418730T1 (de) 1998-08-20 2009-01-15 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von potenziellen verbindungen für das auffinden von einem anti- tumor-arzneistoff
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1182083C (zh) 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
EP1463501B1 (en) 2001-12-18 2008-06-11 F. Hoffmann-La Roche AG Cis-imidazolines as mdm2 inhibitors
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
JP4023184B2 (ja) 2002-03-11 2007-12-19 昭和電工株式会社 発光体粒子及びその製造方法並びにその用途
US7514579B2 (en) 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
AU2003291269A1 (en) 2002-11-08 2004-06-03 Irm Llc Methods and compositions for modulating p53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
AU2004212928A1 (en) 2003-02-13 2004-09-02 Bioveris Corporation Deazaflavin compounds and methods of use thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
NZ601780A (en) 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
WO2005063774A1 (en) 2003-12-22 2005-07-14 Johns Hopkins University Boronic acid aryl analogs
US8598127B2 (en) 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
KR100832277B1 (ko) 2004-05-18 2008-05-26 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
US7834016B2 (en) 2004-09-22 2010-11-16 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
AU2006216780B8 (en) * 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
PT1891075E (pt) 2005-05-24 2011-11-10 Merck Serono Sa Derivados espiro tricíclicos como moduladores do crth2
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
ES2350504T3 (es) * 2006-03-13 2011-01-24 F. Hoffmann-La Roche Ag Derivados de espiroindolinona.
JP5385125B2 (ja) 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
ES2425965T3 (es) 2006-08-30 2013-10-18 The Regents Of The University Of Michigan Nuevos inhibidores de moléculas pequeñas de MDM2 y usos de los mismos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US8002528B2 (en) * 2006-09-18 2011-08-23 Emerson Climate Technologies, Inc. Compressor assembly having vibration attenuating structure
BRPI0717266A2 (pt) * 2006-09-21 2014-12-09 Hoffmann La Roche Derivados de oxindol
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
KR20090090383A (ko) 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
EA200901212A1 (ru) 2007-03-29 2010-04-30 Новартис Аг 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009037343A1 (en) 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
RU2360914C1 (ru) * 2007-10-31 2009-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Анальгетическое средство
CZ301561B6 (cs) 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
NZ600430A (en) * 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのｍｄｍ２阻害剤のバイオマーカー
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
CN103298818B (zh) * 2010-11-12 2016-06-29 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂

Also Published As

Publication number Publication date
NI201200083A (es) 2012-10-29
MA33815B1 (fr) 2012-12-03
BR112012011317A2 (pt) 2019-09-24
AU2010319595A1 (en) 2012-06-28
NZ600430A (en) 2014-06-27
UY33029A (es) 2011-06-30
JP2013510860A (ja) 2013-03-28
AR079026A1 (es) 2011-12-21
GT201200147A (es) 2014-08-26
CN102712650A (zh) 2012-10-03
IL219706A (en) 2016-07-31
DOP2012000131A (es) 2012-09-30
US20140378680A1 (en) 2014-12-25
US9079913B2 (en) 2015-07-14
TWI508967B (zh) 2015-11-21
EP2499145A4 (en) 2013-07-10
WO2011060049A3 (en) 2011-10-20
CN104876938A (zh) 2015-09-02
TN2012000161A1 (en) 2013-12-12
US20110112052A1 (en) 2011-05-12
CR20120313A (es) 2012-07-24
US20130296303A1 (en) 2013-11-07
RU2012124056A (ru) 2013-12-20
EP2499145A2 (en) 2012-09-19
CA2780547C (en) 2015-02-03
CL2012001250A1 (es) 2012-11-30
RU2553269C2 (ru) 2015-06-10
EP2499145B1 (en) 2016-01-27
WO2011060049A2 (en) 2011-05-19
PH12012500870A1 (en) 2012-11-26
CO6501131A2 (es) 2012-08-15
MX2012005507A (es) 2012-07-03
PE20121282A1 (es) 2012-10-12
CN102712650B (zh) 2015-05-20
ECSP12011943A (es) 2012-07-31
CA2780547A1 (en) 2011-05-19
US8518984B2 (en) 2013-08-27
ZA201203323B (en) 2013-01-30
AU2010319595B2 (en) 2015-09-17
IL219706A0 (en) 2012-07-31
TW201129570A (en) 2011-09-01
US8877796B2 (en) 2014-11-04
KR20120099462A (ko) 2012-09-10

Similar Documents

Publication Publication Date Title
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
IN2012MN02591A (uk)
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201290919A1 (ru) Индазольные соединения и их применение
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201270722A1 (ru) Формы рифаксимина и их применение
MX2011009847A (es) Agentes antihelminticos y su uso.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
GB2511685A (en) Muscarinic m1 receptor agonists
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
EA201270727A1 (ru) Пуриновые соединения
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists